Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.51 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.45 |
| ▸ | PARP1 | P09874 | 7/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.42 |
| ▸ | PIM1 | P11309 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.42 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4376398 | 1.00 | SRC (0.51) | SRCENPP1PARP1CHEK1PIM1 | |
| Hydrochloric Acid SCHEMBL27988002 | 0.99 | SRC (0.50) | SRCENPP1PARP1CHEK1PIM1 | |
| SCHEMBL4375769 | 0.96 | SRC (0.50) | SRCENPP1PARP1CHEK1PIM1 | |
| SCHEMBL664912 | 0.95 | SRC (0.51) | SRCENPP1PARP1CHEK1PIM1 | |
| SCHEMBL12310510 | 0.89 | SRC (0.51) | SRCENPP1PARP1CHEK1PIM1 | |
| SCHEMBL13299042 | 0.89 | SRC (0.51) | SRCENPP1PARP1CHEK1PIM1 | |
| SCHEMBL13787116 | 0.89 | SRC (0.53) | SRCENPP1PARP1CHEK1PIM1 | |
| SCHEMBL14690985 | 0.88 | SRC (0.50) | SRCENPP1PARP1CHEK1PIM1 | |
| SCHEMBL4297393 | 0.88 | SRC (0.50) | SRCENPP1PARP1CHEK1PIM1 | |
| SCHEMBL1780281 | 0.88 | SRC (0.52) | SRCKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1477481-B1 | PROCESS FOR PRODUCING QUINAZOLIN-4-ONE DERIVATIVE | UBE INDUSTRIES (JP) | 2009-07-22 | — | — | EP | claimed |
| US-20050080262-A1 | Process for producing quinazolin-4-one derivative | UBE INDUSTRIES, LTD. (JP) | 2005-04-14 | — | — | US | claimed |
| EP-1477481-A1 | PROCESS FOR PRODUCING QUINAZOLIN-4-ONE DERIVATIVE | Ube Industries, Ltd. (JP) | 2004-11-17 | — | — | EP | claimed |
| US-8367824-B2 | Reacting anthranilic acid with formic acid compound in presence of a catalyst and solvent | UBE INDUSTRIES LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-8367824-B2 | Reacting anthranilic acid with formic acid compound in presence of a catalyst and solvent | UBE INDUSTRIES LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-8350029-B2 | Process for the preparation of gefitinib | CIPLA LIMITED (IN) | 2013-01-08 | — | — | US | disclosed |
| US-8350029-B2 | Process for the preparation of gefitinib | CIPLA LIMITED (IN) | 2013-01-08 | — | — | US | disclosed |
| US-20100137586-A1 | Process for the Preparation of Gefitinib | CIPLA LIMITED (IN) | 2010-06-03 | — | — | US | disclosed |
| US-20100137586-A1 | Process for the Preparation of Gefitinib | CIPLA LIMITED (IN) | 2010-06-03 | — | — | US | disclosed |
| EP-2155656-A2 | PROCESS FOR THE PREPARATION OF GEFITINIB | Cipla Limited (IN) | 2010-02-24 | — | — | EP | disclosed |
| EP-1477481-B1 | PROCESS FOR PRODUCING QUINAZOLIN-4-ONE DERIVATIVE | UBE INDUSTRIES (JP) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008125867-A2 | PROCESS FOR THE PREPARATION OF GEFITINIB | CIPLA LIMITED (IN) | 2008-10-23 | — | — | WO | disclosed |
| US-20050080262-A1 | Process for producing quinazolin-4-one derivative | UBE INDUSTRIES, LTD. (JP) | 2005-04-14 | — | — | US | disclosed |
| EP-1477481-A1 | PROCESS FOR PRODUCING QUINAZOLIN-4-ONE DERIVATIVE | Ube Industries, Ltd. (JP) | 2004-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137586-A1 | Process for the Preparation of Gefitinib | EGFR, BRAF, KRAS | SRC 243/4885ENPP1 3884/4885PARP1 1662/4885 |
| US-20050080262-A1 | Process for producing quinazolin-4-one derivative | NQO2, SDHA, CYP3A4 | SRC 2055/4885ENPP1 3684/4885PARP1 712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.